All News
Filter News
Found 2,517 articles
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer
5/3/2018
Caribou Biosciences, Inc. announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer.
-
Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.
-
ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Evotec
5/2/2018
ERS Genomics announced a patent license agreement with Hamburg-based Evotec AG, which gains non-exclusive access to the Company’s CRISPR/Cas9 patents to expand their research services offering.
-
Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics
5/2/2018
Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited.
-
Free Research Reports on These Biotech Stocks -- Exelixis, INSYS Therapeutics, Intellia Therapeutics, and Intercept Pharma
5/2/2018
WallStEquities.com is offering reports on EXEL, INSY, NTLA, and ICPT which can be accessed for free by signing up to www.wallstequities.com/registration.
-
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
5/2/2018
IONTAS Limited and Ten Therapeutics Limitedannounced that they have entered into a strategic collaboration.
-
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
5/2/2018
Refuge Biotechnologies, Inc. announced the closing of a $25 million Series B investment round.
-
Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.
-
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
-
Global Genome Editing Market - Industry Analysis and Forecast| Technavio
4/30/2018
Technavio’s latest market research report on the global genome editing market provides an analysis of the most important trends expected to impact the market outlook from 2018-2022.
-
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
-
Vertex Reports First-Quarter 2018 Financial Results
4/26/2018
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
-
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
4/24/2018
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation
-
CAR-T Trailblazer Carl June Who Collaborated on Novartis’ Kymriah Makes Time's 100 Influential List
4/23/2018
A pioneer in CAR-T therapies has been named one of Time Magazine’s 100 most influential people in the world for 2018. -
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
-
The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
-
Synthego Appoints CRISPR Pioneer Dr. Jennifer Doudna to Advisory Board to Accelerate Company's Genome Engineering Mission
3/28/2018
Doudna to advise Synthego as the company develops technology and services to further the adoption of CRISPR, bringing access, precision and automation to genome engineering
-
Kaleido Biosciences Announces Appointments to Leadership Team
3/26/2018
Stephen Sofen, Ph.D. to head technical operations and Susan Stewart, J.D. to lead regulatory affairs and quality
-
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
3/22/2018
CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to CureVac on GMP-conforming pharmaceutical manufacturing methods for producing RNA